A clinical study was conducted to determine the safety and efficacy of neoadjuvant erlotinib
treatment in patients with head and neck squamous cell carcinoma [Thomas F, Rochaix P …

Generally, licensed drug‐dosing recommendations for chemotherapy are based on results
from clinical trials in which subjects are usually of relatively normal body size, middle‐aged …

Dose–response analysis is often applied to the quantification of drug‐effect especially for
slowly responding disease end points where a comparison is made across dose levels after …

1E10, 101M; AAV-ASPA, agomelatine, aliskiren fumarate, alvimopan hydrate, ambrisentan,
apaziquone, axitinib; Becatecarin, belagenpumatucel-L, BMS-201038; Cannabidiol …

Two small-molecule epidermal growth factor receptor tyrosine kinase inhibitors, gefitinib and
erlotinib, have been approved for the treatment of non-small-cell lung cancer. Here, we …

Erlotinib is currently marketed at fixed standard dosage against pancreatic cancer and non–
small-cell lung carcinoma. However, erlotinib pharmacokinetics (PK) is characterized by …

Proof of the concept that molecular-targeted therapy is a valid therapeutic approach for head
and neck squamous cell carcinoma has emerged with anti-epidermal growth factor receptor …

The number of trials conducted and the number of patients per trial are typically small in
paediatric clinical studies. This is due to ethical constraints and the complexity of the medical …

Current development of molecular targeted therapies in oncology is particularly active. The
aim of this study is to review recent advances in the field of molecular targeted therapies for …

We performed a clinical trial in patients with non–muscle-invasive (NMI) urothelial cancer
randomized (2: 1) to the EGFR tyrosine kinase inhibitor erlotinib or placebo (either orally …